Mechanisms of Hearing Loss in Neurofibromatosis Type 2

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Asthagiri, Ashok R ^a   Vasquez, Raul A ^a,b   Butman, John A ^c   Wu, Tianxia ^a   Morgan, Keaton ^a   Brewer, Carmen C ^d   King, Kelly ^d   Zalewski, Chris ^d   Kim, H Jeffrey ^d   Lonser, Russell R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTRALABYRINTHINE PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; AUDIOMETRY; CHILD; CLINICAL EXAMINATION; COCHLEAR APERTURE OBSTRUCTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEARING IMPAIRMENT; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; INNER EAR; INNER EAR DISEASE; MAJOR CLINICAL STUDY; MALE; MENIERE DISEASE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN CONTENT; SCHOOL CHILD; THREE DIMENSIONAL IMAGING; TUMOR VOLUME; VESTIBULOCOCHLEAR SCHWANNOMA;

CROSS-SECTIONAL STUDIES; HEARING LOSS; HUMANS; NEUROFIBROMATOSIS 2; PROSPECTIVE STUDIES;

EID: 84866873295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046132     Document Type: Article

References (36)

1. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75: 826.
2. Evans DG, Huson SM, Donnai D, Neary W, Blair V, et al. (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29: 841-846.
3. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, et al. (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26: 93-97.
4. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, et al. (2009) Neurofibromatosis type 2. Lancet 373: 1974-1986.
5. Evans DG, Huson SM, Donnai D, Neary W, Blair V, et al. (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84: 603-618.
6. Abaza MM, Makariou E, Armstrong M, Lalwani AK, (1996) Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. The Laryngoscope 106: 694-699.
7. Fisher LM, Doherty JK, Lev MH, Slattery WH, (2009) Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol 30: 835-841.
8. Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH, (2004) Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 25: 150-154.
9. Graamans K, Van Dijk JE, Janssen LW, (2003) Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta oto-laryngologica 123: 51-54.
10. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, et al. (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759-1765.
11. King KA, Makishima T, Zalewski CK, Bakalov VK, Griffith AJ, et al. (2007) Analysis of auditory phenotype and karyotype in 200 females with Turner syndrome. Ear and hearing 28: 831-841.
12. Melhem ER, Jara H, Eustace S, (1997) Fluid-attenuated inversion recovery MR imaging: identification of protein concentration thresholds for CSF hyperintensity. AJR Am J Roentgenol 169: 859-862.
13. Butman JA, Kim HJ, Baggenstos M, Ammerman JM, Dambrosia J, et al. (2007) Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA 298: 41-48.
14. Tagaya M, Yamazaki M, Teranishi M, Naganawa S, Yoshida T, et al. (2011) Endolymphatic hydrops and blood-labyrinth barrier in Meniere's disease. Acta Otolaryngol 131: 474-479.
15. Nakashima T, Naganawa S, Teranishi M, Tagaya M, Nakata S, et al. (2010) Endolymphatic hydrops revealed by intravenous gadolinium injection in patients with Meniere's disease. Acta Otolaryngol 130: 338-343.
16. Slattery WH, Lev MH, Fisher LM, Connell SS, Iqbal Z, et al. (2005) MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol 26: 733-740.
17. Lundin P, Pedersen F, (1992) Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16: 519-528.
18. Silverstein H, (1973) Labyrinthine tap as a diagnostic test for acoustic neurinoma. OTOLARYNGCLINNAMER 6: 229-244.
19. Yoshida T, Sugiura M, Naganawa S, Teranishi M, Nakata S, et al. (2008) Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging findings and prognosis in sudden sensorineural hearing loss. The Laryngoscope 118: 1433-1437.
20. Yamazaki M, Naganawa S, Kawai H, Nihashi T, Fukatsu H, et al. (2009) Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma. Neuroradiology 51: 855-863.
21. Gardner WJ, Spitler DK, Whitten C, (1954) Increased intracranial pressure caused by increased protein content in the cerebrospinal fluid; an explanation of papilledema in certain cases of small intracranial and intraspinal tumors, and in the Guillain-Barre syndrome. The New England journal of medicine 250: 932-936.
22. Froin G, (1903) Inflammations méningées avec reaction chromatique, fibrineuse et cytologique du liquide céphalo-rachidien. Gaz d hop 76.
23. Shepherd RK, Colreavy MP, (2004) Surface microstructure of the perilymphatic space: implications for cochlear implants and cell- or drug-based therapies. Archives of otolaryngology-head & neck surgery 130: 518-523.
24. Wenthold RJ, McGarvey ML, (1982) Changes in rapidly transported proteins in the auditory nerve after hair cell loss. Brain research 253: 263-269.
25. Thomsen J, Saxtrup O, Tos M, (1982) Quantitated determination of proteins in perilymph in patients with acoustic neuromas. ORL; journal for oto-rhino-laryngology and its related specialties 44: 61-65.
26. Butman JA, Linehan WM, Lonser RR, (2008) Neurologic manifestations of von Hippel-Lindau disease. JAMA: the journal of the American Medical Association 300: 1334-1342.
27. Lysaght AC, Kao SY, Paulo JA, Merchant SN, Steen H, et al. (2011) Proteome of human perilymph. Journal of proteome research 10: 3845-3851.
28. Eckermeier L, Pirsig W, Mueller D, (1979) Histopathology of 30 non-operated acoustic schwannomas. Archives of oto-rhino-laryngology 222: 1-9.
29. Schuknecht HF, Ishii T, (1966) Hearing loss caused by atrophy of the stria vascularis. Nihon Jibiinkoka Gakkai kaiho 69: 1825-1833.
30. Silverstein H, Schuknecht HF, (1966) Biochemical studies of inner ear fluid in man. Changes in otosclerosis, Meniere's disease, and acoustic neuroma. Archives of otolaryngology 84: 395-402.
31. Dix MR, Hallpike CS, (1950) Observations on the pathological mechanism of conductive deafness in certain cases of neuroma of the VIIIth nerve. The Journal of laryngology and otology 64: 658-666.
32. Graamans K, Van Dijk JE, Janssen LW, (2003) Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta oto-laryngologica 123: 51-54.
33. Pennings RJE, Morris DP, Clarke L, Allen S, Walling S, et al. (2011) Natural history of hearing deterioration in intracanalicular vestibular schwannoma. Neurosurgery 68: 68-77.
34. Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN, (2012) Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 33: 473-480.
35. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, et al. (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. The New England journal of medicine 361: 358-367.
36. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, et al. (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 33: 1046-1052.